icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
hSXEHSuDZ0CA5DAA
Listen
